Get the Stockscreener App
0.5509
8.31%
-0.0499
Evogene Ltd stock is traded at $0.5509, with a volume of 292.23K.
It is down -8.31% in the last 24 hours and down -12.42% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
See More
Previous Close:
$0.6008
Open:
$0.6163
24h Volume:
292.23K
Relative Volume:
0.17
Market Cap:
$8.70M
Revenue:
$1.84M
Net Income/Loss:
$-17.51M
P/E Ratio:
-0.3978
EPS:
-1.3849
Net Cash Flow:
$-17.30M
1W Performance:
-12.87%
1M Performance:
-12.42%
6M Performance:
-43.56%
1Y Performance:
-59.19%
1-Day Range:
$0.5409
$0.6265
1-Week Range:
$0.5409
$0.7022
52-Week Range:
$0.37
$1.50
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
0.5509 | 9.49M | 1.84M | -17.51M | -17.30M | -1.3849 |
VRTX
Vertex Pharmaceuticals Inc
|
515.50 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.71 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.46 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.24 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.25 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Earnings To Watch: Evogene Ltd (EVGN) Q2 2026 -- GF Value Sees 15% Downside - Yahoo Finance
Freightos Names Yaron Eldad as Chief Financial Officer - marketscreener.com
EVGN Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Armistice Capital (EVGN) discloses 4.99% beneficial stake in Evogene shares - Stock Titan
Evogene chairman to address dissident shareholder issues in Aug 18 earnings call - Pluang
Evogene Chairman Joins Company Results Call on August 18 - Stock Titan
Why Did EVGN Shares Drop More Than 14% Today? - Stocktwits
Evogene Ltd. (EVGN) investors lift beneficial stake to 19.35% of shares - Stock Titan
Evogene (EVGN): Director Leon Recanati buys 460,000 shares, now holds 8.6% - Stock Titan
Evogene (EVGN) director Leon Recanati buys 460,000 shares and reports option holdings - Stock Titan
Earnings Preview: Evogene to Report Financial Results Pre-market on August 18 - Moomoo
Leon Recanati Discloses Investment at Evogene Ltd. with 5.7% Stake - TradingView
Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7% - Stock Titan
Evogene (EVGN) Insider Trading Activity 2026 - MarketBeat
Evogene Ltd. (EVGN) investor group boosts ownership to 15.98% - Stock Titan
Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Evogene (NASDAQ: EVGN) Share Price, EVGN Stock News, EVGN Share Price & Updates - Kalkine
Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy - Stock Titan
ICL and Lavie Bio leverage AI for the development of yield increasing Bio-Stimulants - agrospectrumindia.com
Evogene Sets Sept. 4 AGM Amid Board Contest and VP Departure - The Globe and Mail
Evogene Ltd. Revenue Breakdown – NASDAQ:EVGN - TradingView
Evogene (Nasdaq: EVGN) faces proxy slate battle and reverse split decision - Stock Titan
Evogene Ltd (EVGN) Struggles Near Support as Selling Pressure PersistsNarrow Range Breakout - dars.gov.et
Evogene to release Q2 2026 financial results an... - Pluang
Evogene Ltd (EVGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 13D/A Evogene Ltd. For: 27 July By Investing.com - Investing.com South Africa
Evogene Ltd (EVGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Evogene Ltd. (EVGN) holders report 17.41% stake and new ADS buys - Stock Titan
Evogene Ltd (EVGN) Balance Sheet - TradingKey
EVGN|Evogene Ltd|Price:0.542|Chg%:-0.006 - TradingKey
Evogene Ltd (EVGN) Cash Flow - TradingKey
AI is rewiring future of energy cropsOfer Haviv, CEO, Evogene (EVGN) - AgroSpectrum India
Evogene and ELEO join forces to develop next-gen oral PCSK9 drugs targeting billion-dollar cardio market - Indian Pharma Post
EVGN|Evogene Ltd|Price:0.655|Chg%:+0.119 - TradingKey
Evogene Ltd (EVGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Evogene Ltd (EVGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Evogene Ltd (EVGN) Income Statement - TradingKey
Evogene Ltd. (EVGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Evogene Ltd (EVGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Evogene and ELEO to develop new oral PCSK9 inhibitors - Pharmaceutical Business review -
Evogene Ltd. (EVGN) stock price, news, quote and history - Yahoo Finance UK
Evogene and Eleo collaborate to discover PCSK9 pathway inhibitors - BioWorld News
Evogene (EVGN) Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing R&D InvestmentsEarnings Analysis - dars.gov.et
Evogene and ELEO partner on oral PCSK9 inhibitor development By Investing.com - Investing.com South Africa
Evogene & ELEO Partner on Oral PCSK9 Inhibitors - AllSci
Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors - Moomoo
Evogene and ELEO partner on oral PCSK9 inhibitor development - Investing.com
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases – Company Announcement - Financial Times
Evogene stock trades quietly as genomics group leans on cash and recent revenue growth - Ad-hoc-news.de
Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - PR Newswire
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Evogene Ltd Stock (EVGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RECANATI LEON | Director |
Aug 04 '26 |
Buy |
0.50 |
800,000 |
400,000 |
883,886 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):